Last reviewed · How we verify
Esmolol hydrochloride, infusion
At a glance
| Generic name | Esmolol hydrochloride, infusion |
|---|---|
| Sponsor | AOP Orphan Pharmaceuticals AG |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Experienced sedation beyond postanesthesia care unit
- Oxygen requirement beyond postanesthesia care unit
- Experienced vomiting
- Severe bradycardia
- Experienced pruritis
Key clinical trials
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- POCUS-Guided Esmolol in Septic Shock: A Pilot RCT (PHASE1, PHASE2)
- Effect of MGRNOX-Guided General Anesthesia on Opioid Consumption in Patients (NA)
- Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Intracerebral Hemorrhage (PHASE3)
- Age Comparisons of Exercising Muscle O2 Supply in Healthy Adults: Effects of Esmolol Infusion (EARLY_PHASE1)
- Opioids Continue to Play a Primary Role in the Management of Perioperative Pain Due to Opioid-Free Anesthesia in Open Heart Surgery.
- Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery (PHASE4)
- Reduction of Edema With a Specialized Cocktail for Ultra-early Management in Ischemic Stroke (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Esmolol hydrochloride, infusion CI brief — competitive landscape report
- Esmolol hydrochloride, infusion updates RSS · CI watch RSS
- AOP Orphan Pharmaceuticals AG portfolio CI